Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic

Vyriad, Inc. has announced an expansion of a Phase 1 trial at Mayo Clinic for patients with peripheral T-cell lymphoma (PTCL) using Voyager-V1 therapy after encouraging initial results. Regeneron Pharmaceuticals is co-developing the investigational therapy to treat patients with recurrent or treatment resistant cancers by dissolving cancer cells and stimulating the patient's immune system to pre..